Promising cardioprotective effect of baicalin in doxorubicin-induced cardiotoxicity through targeting toll-like receptor 4/nuclear factor-κB and Wnt/β-catenin pathways

•Baicalin ameliorates doxorubicin-induced cardiotoxicity.•Baicalin alleviates cardiac inflammation through down-regulation of Toll-like receptor 4 and nuclear factor kappa B.•Baicalin suppresses Dickkopf-1 and stimulates the Wnt/β-catenin pathway.•Baicalin reduces doxorubicin-induced oxidative stress by restoring the glutathione level and decreasing the malondialdehyde level.